STOCK TITAN

Regeneron Pharmaceuticals Stock Price, News & Analysis

REGN Nasdaq

Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.

Regeneron Pharmaceuticals (NASDAQ: REGN) is a leading biotechnology innovator developing transformative treatments for serious diseases through advanced platforms like VelociSuite®. This page serves as the definitive source for official company announcements, research milestones, and therapeutic developments.

Investors and medical professionals will find curated updates including FDA approvals, clinical trial results, partnership announcements, and financial reports. Our aggregation ensures timely access to Regeneron's progress in oncology, immunology, rare diseases, and ophthalmic therapies.

All content is sourced directly from Regeneron's communications and verified financial disclosures. Bookmark this page to monitor the company's pipeline advancements, regulatory updates, and strategic collaborations that drive biopharmaceutical innovation.

Rhea-AI Summary

Regeneron Pharmaceuticals, Inc. and Sanofi's sBLA for Dupixent® (dupilumab) in adolescents with Chronic Rhinosinusitis with Nasal Polyposis has been accepted for FDA Priority Review. If approved, Dupixent would be the first treatment in the U.S. for this condition in adolescents aged 12-17 years. The target action date for the FDA decision is September 15, 2024. The sBLA is based on positive pivotal trials in adults that showed Dupixent improved nasal congestion, polyp size, sense of smell, and reduced the need for systemic corticosteroids or surgery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
-
Rhea-AI Summary

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced positive preliminary data from the ongoing Phase 1/2 CHORD trial, showing significant hearing improvements in children with genetic deafness who received the investigational gene therapy DB-OTO. One child achieved normal hearing levels within 24 weeks, while another showed initial improvements at 6 weeks. The results were presented at the ASGCT conference, highlighting the potential of DB-OTO as a treatment for otoferlin-related deafness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
none
-
Rhea-AI Summary

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will be participating in investor conferences including the RBC Capital Markets Global Healthcare Conference, Jefferies Global Healthcare Conference, and Goldman Sachs 45th Annual Global Healthcare Conference. The webcasts can be accessed on the company's website, with replays available for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
none
Rhea-AI Summary

Regeneron reported first quarter 2024 financial results with revenues decreasing 1% to $3.15 billion; excluding Ronapreve, revenues increased 7%. Dupixent global net sales rose 24% to $3.08 billion, EYLEA U.S. net sales were $1.40 billion, and Libtayo global net sales increased 45% to $264 million. The company announced a $3.0 billion share repurchase program. Regeneron is progressing well in delivering medicines, advancing its pipeline, and pursuing cutting-edge science, particularly in retinal diseases, oncology, and potential regulatory approvals. Financially, GAAP net income decreased by 12% and non-GAAP diluted EPS decreased by 5%. The company is focusing on innovation and returned $298 million to shareholders through share repurchases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.78%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
conferences earnings

FAQ

What is the current stock price of Regeneron Pharmaceuticals (REGN)?

The current stock price of Regeneron Pharmaceuticals (REGN) is $547.67 as of May 8, 2025.

What is the market cap of Regeneron Pharmaceuticals (REGN)?

The market cap of Regeneron Pharmaceuticals (REGN) is approximately 64.6B.
Regeneron Pharmaceuticals

Nasdaq:REGN

REGN Rankings

REGN Stock Data

64.65B
104.04M
1.58%
91.4%
2.35%
Biotechnology
Pharmaceutical Preparations
Link
United States
TARRYTOWN